Data Sheet (Cat.No.T68139)

TargetMol

Scio-323

Chemical Properties



CAS No. : 309913-51-7

Formula: C27H30FN3O4

Molecular Weight: 479.54

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Scio-323 is an orally available p38 mitogen-activated protein (MAPK) kinase inhibitor.
Targets(IC50)	Endogenous Metabolite,p38 MAPK
In vivo	Oral treatment with the SCIO-323 included delivery for 3 weeks and stopping for 3 weeks, delivery for 3 weeks after an initial 3-week delay, and delivery for 6 weeks continuously. Administration of the SCIO-323 continuously for 6 weeks with/without the presence of particles, or for the initial 3 of 6 weeks had minor effects on bone ingrowth. After establishing a particle-induced chronic inflammatory reaction for 3 weeks, administration of SCIO-323 for a subsequent 3 weeks suppressed net bone formation. The activity of osteoclast-like cells remained low among all treatments when compared with the first control.[1]

Solubility Information

Solubility	DMSO: 27.5 mg/mL (57.35 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0853 mL	10.4267 mL	20.8533 mL
5 mM	0.4171 mL	2.0853 mL	4.1707 mL
10 mM	0.2085 mL	1.0427 mL	2.0853 mL
50 mM	0.0417 mL	0.2085 mL	0.4171 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ma T, et al. Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo. J Biomed Mater Res A. 2009;89(1):117-123.
Kirschenbaum, et al. Methods of screening for compounds that selectively inhibit p38 MAP kinase α isoenzymes for use as immunomodulators. US20050043212A1
Higgins, et al. Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase. US20060058296A1.